 After two rejections, Fennec Pharmaceuticals finally secured FDA approval for its only asset, Pedmark. Additionally, the company secured non-dilutive capital to help initial commercialization efforts. While the market for Pedmark is limited, its critical use in the prevention of cisplatin-related hearing loss in pediatric patients assures market viability. 